DGX Quest Diagnostics Incorporated

$178.40

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Quest Diagnostics Incorporated

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Website: https://www.questdiagnostics.com

Sector
LIFE SCIENCES
Industry
SERVICES-MEDICAL LABORATORIES
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1022079
Address
500 PLAZA DRIVE, SECAUCUS, NJ, US
Valuation
Market Cap
$18.18B
P/E Ratio
21.33
PEG Ratio
1.48
Price to Book
2.68
Performance
EPS
$7.68
Dividend Yield
1.95%
Profit Margin
8.82%
ROE
13.80%
Technicals
50D MA
$168.63
200D MA
$156.92
52W High
$178.00
52W Low
$125.83
Fundamentals
Shares Outstanding
111M
Target Price
$179.27
Beta
0.78

DGX EPS Estimates vs Actual

● Estimated
● Actual

DGX News & Sentiment

Oct 03, 2025 • Zacks Commentary BULLISH
Why Quest Diagnostics ( DGX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Oct 01, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
Sep 30, 2025 • Zacks Commentary NEUTRAL
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Here's Why Quest Diagnostics ( DGX ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment Snapshot

Average Sentiment Score:

0.312
50 articles with scored sentiment

Overall Sentiment:

Bullish

DGX Reported Earnings

Apr 21, 2025
Mar 31, 2025 (Pre market)
0.06 Surprise
  • Reported EPS: $2.21
  • Estimate: $2.15
  • Whisper: —
  • Surprise %: 2.8%
Jan 30, 2025
Dec 31, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $2.23
  • Estimate: $2.18
  • Whisper: —
  • Surprise %: 2.1%
Oct 22, 2024
Sep 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $2.30
  • Estimate: $2.26
  • Whisper: —
  • Surprise %: 1.8%
Jul 23, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $2.35
  • Estimate: $2.34
  • Whisper: —
  • Surprise %: 0.4%
Apr 23, 2024
Mar 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $2.04
  • Estimate: $1.86
  • Whisper: —
  • Surprise %: 9.7%
Feb 01, 2024
Dec 31, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $2.15
  • Estimate: $2.11
  • Whisper: —
  • Surprise %: 1.9%
Oct 24, 2023
Sep 30, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $2.22
  • Estimate: $2.19
  • Whisper: —
  • Surprise %: 1.4%
Jul 26, 2023
Jun 30, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $2.30
  • Estimate: $2.27
  • Whisper: —
  • Surprise %: 1.3%
Apr 27, 2023
Mar 31, 2023 (Pre market)
0.07 Surprise
  • Reported EPS: $2.04
  • Estimate: $1.97
  • Whisper: —
  • Surprise %: 3.5%

Financials